Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial
Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Nov 30, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether two types of enemas—antegrade and retrograde—can help prevent a condition called Low Anterior Resection Syndrome (LARS) in adults who have had surgery for rectal cancer. LARS can cause issues with bowel function and affect quality of life after surgery. Researchers want to find out if these enemas can improve bowel function, sleep quality, and overall well-being after surgery compared to the standard care, which involves no enema.
To participate in this study, you need to be at least 18 years old and have been diagnosed with primary rectal adenocarcinoma. You should also have undergone surgery for rectal cancer with a temporary ileostomy. If you join, you will receive either an antegrade enema, a retrograde enema, or standard care about one month after your surgery. During the study, you'll keep a diary to track your symptoms. The trial is not yet recruiting participants, but it aims to help improve the lives of patients recovering from rectal cancer surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Based on the NCCN guidelines for the pathological diagnosis of rectal cancer, patients are identified as having Primary Rectal Adenocarcinoma.
- • ≥18 years.
- • For the first time, anterior rectal dissection combined with prophylactic ileostomy was performed using laparoscopic, robotic, and open techniques.
- • The patient exhibits normal cognitive and expressive abilities.
- • Informed consent was obtained for voluntary participation in the study.
- Exclusion Criteria:
- • American Society of Anesthesiologists (ASA) Class III or higher.
- • A combination of other intestinal conditions, including inflammatory bowel disease and Crohn's disease.
- • Mental disorders and prolonged use of psychotropic medications.
- • The presence of contraindications to enema administration.
About Sichuan Cancer Hospital And Research Institute
Sichuan Cancer Hospital and Research Institute is a leading comprehensive cancer treatment and research facility located in Chengdu, China. Renowned for its commitment to advancing oncology, the institute integrates clinical practice with cutting-edge research to develop innovative treatment protocols and enhance patient care. With a multidisciplinary team of experts, the hospital focuses on a wide range of cancer therapies, including surgical, medical, and radiation oncology, while also actively participating in clinical trials to contribute to the global understanding of cancer management. Its state-of-the-art facilities and dedication to research make it a pivotal player in the fight against cancer in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported